After Hours Summary: ADBE +5%, KBH +4% following earnings/guidance, SPSC +6%, FOXF +3% and COO +1% on S&P index news, MSFT +1.2% on dividend/buyback news... MSTX -80% Ph 3 trial updateAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: ADBE +4.7%, KBH +4.2%, AIRG +4.2%, NUS +3.6% (reaches resolution with the SEC, which fully resolves the previously disclosed SEC investigation in its entirety; sees Q3 revs at high end or above prior guidance), FDX +2.2%, CAFD +0.3% (also 8point3 Energy Partners LP to acquire Sunpower's 49% stake in its 102-MW Henrietta Solar Project for about $134 mln)
Companies trading higher in after hours in reaction to news: USEG +10.1% (thinly traded, entered into an Earnings & Participation Agreement on a previously announced project with IronHorse Resources), CLVS +8.2% (continued strength following today's M&A chatter), SPSC +5.6% (to join S&P SmallCap 600), ADMS +5% (announces results of EASE LID 3, says the improvement in LID was statistically significant and confirmed safety and efficacy data from earlier pivotal trials), FOXF +2.5% (light volume - to join S&P SmallCap 600), KITE +1.6% (enters an exclusive, worldwide license with the NIH for intellectual property related to multiple T-cell receptor based product candidates for the treatment of tumors expressing mutated KRAS antigens), MSFT +1.2% (dividend increased 8 percent; $40 billion authorized for share repurchase), COO +0.9% (to join the S&P 500), UPS +0.6% (following FDX earnings), CAFD +0.3% (8point3 Energy Partners LP to acquire 49% stake in 102-MW Henrietta Solar Project for about $134 mln), AGN +0.2% (Allergan acquires Akarna Therapeutics for an up-front payment of $50 mln)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: N/A
Companies trading lower in after hours in reaction to news: MSTX -79.7% (reports top-line results from Phase 3 study in sickle cell disease; study did not meet its primary efficacy endpoint; will hold a conference call tomorrow), MIRN -26.8% (to close the ongoing Phase 1 study of MRX34, its investigational microRNA therapy for multiple cancers), LEI -4.3% (ticking lower; files for 13,009,664 share common stock offering pursuant to the asset purchase agreement by selling stockholders), CDNA -3.5% (announces a proposed offering of common stock), COMM -0.9% (announces sale of 10 mln shares of common stock by affiliate of The Carlyle Group)